1-(4-aminophenyl)-3-(4-fluorophenyl)urea | 849666-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-aminophenyl)-3-(4-fluorophenyl)urea
• 英文别名: N-(4-aminophenyl)-N′-(4-fluorophenyl)urea
• CAS: 849666-45-1
• 化学式: C₁₃H₁₂FN₃O
• mdl: MFCD09050715
• 分子量: 245.256
• InChiKey: FRTRMDKMFOBCMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  319.8±27.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-aminophenyl)-3-(4-fluorophenyl)urea 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 9.0h， 生成 (E)-1-(4-fluorophenyl)-3-(4-(4-(morpholin-4-yl)-6-(4-chlorostyrenyl)-1,3,5-triazinyl-2-amino)phenyl)urea
  参考文献：
  名称：

  SARs of a novel series of s-triazine compounds targeting vimentin to induce methuotic phenotype

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113188
• 作为产物：
  描述：

  异氰酸对硝基苯 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 生成 1-(4-aminophenyl)-3-(4-fluorophenyl)urea
  参考文献：
  名称：

  以噻吩并嘧啶骨架为靶标的某些VEGFR-2抑制剂的设计，合成和分子模型研究

  摘要：

  设计，合成和评价了不同系列的新型噻吩并[2，3- d ]嘧啶衍生物（9a-d，10a-f，l，m和15a-m）在体外抑制VEGFR-2酶的能力。而且，通过NCI对60种不同的人类癌细胞系进行了测试，以测试最终化合物的细胞毒性。VEGFR-2酶的抑制结果表明，化合物10d，15d和15 g是活性最高的抑制剂，IC 50值分别为2.5、5.48和2.27 µM，而化合物10a显着显示出最高的细胞生长抑制率，平均生长抑制率（GI）为31.57％。它对几种NCI细胞系表现出广谱的抗增殖活性，特别是对人乳腺癌（T7-47D）和肾癌（A498）细胞系分别具有85.5％和77.65％的抑制作用。为了研究该活性的机制，对化合物10a进行了进一步的生物学研究，例如流式细胞术细胞周期与caspase-3比色测定。对MCV-7和PC-3癌细胞的流式细胞仪分析表明，它诱导了G0-G1期的细胞周期停滞，并通过激活c

  DOI：

  10.1016/j.bioorg.2018.10.008

文献信息

• Synthesis and Cytotoxic Activity of Biphenylurea Derivatives Containing Indolin-2-one Moieties
  作者：Wagdy Eldehna、Mohamed Fares、Hany Ibrahim、Muhammad Alsherbiny、Mohamed Aly、Hazem Ghabbour、Hatem Abdel-Aziz

  DOI：10.3390/molecules21060762

  日期：——

  compounds. Compound 5o (IC50 = 1.04 ± 0.10 μM) emerged as the most active member in this study against MCF-7, with 7-fold increased activity compared to the reference drug, doxorubicin (IC50 = 7.30 ± 0.84 μM). Compounds 5l, 5q and 8b also exhibited superior cytotoxic activity against MCF-7 with IC50 values of 1.93 ± 0.17, 3.87 ± 0.31 and 4.66 ± 0.42 μM, respectively. All of the tested compounds were filtered

  在我们致力于开发有效抗癌剂的过程中，我们合成了两组不同的联苯脲-吲哚满酮缀合物，5a-s 和 8a,b。使用磺基罗丹明 B (SRB) 比色法在两种人类癌细胞系，即 MCF-7 乳腺癌和 PC-3 前列腺癌细胞中检查合成化合物的体外细胞毒性。特别是，MCF-7 癌细胞系对合成的化合物更敏感。化合物 5o (IC50 = 1.04 ± 0.10 μM) 成为本研究中针对 MCF-7 最活跃的成员，与参考药物多柔比星 (IC50 = 7.30 ± 0.84 μM) 相比，活性增加了 7 倍。化合物 5l、5q 和 8b 还对 MCF-7 表现出优异的细胞毒活性，IC50 值分别为 1.93 ± 0.17、3.87 ± 0.31 和 4.66 ± 0.42 μM。根据Lipinski 和Veber 规则过滤所有测试化合物，并且它们都通过过滤器。此外，通过使用 Discovery Studio 2
• Phenyl and Diaryl Ureas with Thiazolo[5,4‐ <i>d</i> ]pyrimidine Scaffold as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation
  作者：Wen‐Jun Xue、Ya‐Hui Deng、Zhong‐Hui Yan、Ji‐Ping Liu、Yu Liu、Li‐Ping Sun

  DOI：10.1002/cbdv.201800493

  日期：2019.4

  receptor‐2 (VEGFR‐2) is an important factor in angiogenesis. In this work, a novel series of thiazolo[5,4‐d]pyrimidine derivatives inhibiting angiogenesis were rationally designed and synthesized. Their inhibitory activities against human umbilical vein endothelial cells (HUVEC) were investigated in vitro. 1‐(4‐Fluorophenyl)‐3‐4‐[(5‐methyl‐2‐phenyl[1,3]thiazolo[5,4‐d]pyrimidin‐7‐yl)amino]phenyl}urea (19b)

  血管生成对肿瘤生长至关重要，抑制血管生成已被视为癌症治疗的一种有前途的方法。血管内皮生长因子受体-2 (VEGFR-2) 是血管生成的重要因素。在这项工作中，合理设计和合成了一系列抑制血管生成的新型噻唑并[5,4-d]嘧啶衍生物。在体外研究了它们对人脐静脉内皮细胞 (HUVEC) 的抑制活性。1-(4-氟苯基)-3-4-[(5-甲基-2-苯基[1,3]噻唑并[5,4-d]嘧啶-7-基)氨基]苯基}脲(19b)和1-(3-氟苯基)-3-4-[(5-methyl-2-phenyl[1,3]thiazolo[5,4-d]pyrimidin-7-yl)amino]phenyl}urea (19g)对 HUVEC 增殖最有效的抑制作用（IC50 分别为 12.8 和 5.3 μm）。化合物19g可抑制人脐静脉内皮细胞的迁移。这些结果支持进一步研究这些化合物作为有效的抗癌剂。
• Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials
  作者：Borvornwat Toviwek、Jennifer Riley、Nicole Mutter、Mark Anderson、Lauren Webster、Irene Hallyburton、Duangkamol Gleeson、Kevin D. Read、M. Paul Gleeson

  DOI：10.1039/d2md00218c

  日期：——

  were also undertaken. Compounds 40 demonstrated the best anti-malarial activity at Pf 3D7 (0.09 μM), good selectivity with respect to mammalian cytotoxicity (SI = 54) and low microsomal clearance. Quantitative structure activity relationship (QSAR) analyses point to lipophilicity being a key driver of improved anti-malarial activity. The most active compounds in the series suffered from high lipophilicity

  报道了26 种新的苯脲取代的 2,4-二氨基嘧啶的合成和抗恶性疟原虫( Pf ) 3D7 的评价。制备化合物以提高我们小组先前报道的系列的抗疟活性和选择性。已确定其他特性来评估其作为抗疟疾先导药物的潜力，包括：HepG2 细胞毒性、溶解度、渗透性和亲脂性，以及在人和大鼠微粒体中的体外稳定性。我们还评估了它们对 10 种不同人类激酶的抑制特性。还进行了分子对接、化学信息学和生物信息学分析。化合物40在Pf 3D7 (0.09 μM)下表现出最佳的抗疟活性、对哺乳动物细胞毒性的良好选择性 (SI = 54) 和较低的微粒体清除率。定量结构活性关系（QSAR）分析指出亲脂性是改善抗疟疾活性的关键驱动因素。该系列中最活性的化合物具有高亲脂性、差水溶性和低渗透性。结果提供了有用的信息来指导进一步的化学迭代。
• Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors
  作者：Soha R. Abd El Hadi、Deena S. Lasheen、Dalia H. Soliman、Eman Z. Elrazaz、Khaled A.M. Abouzid

  DOI：10.1016/j.bioorg.2020.103961

  日期：2020.8

  In our attempt to discover effective anticancer agents, three series of novel quinazoline-based compounds have been designed, synthesized and tested as VEGFR-2 inhibitors. Five quinazoline -2-carboxamide derivatives (5d, 5e, 5 h, 5i, 5j) revealed potent nanomolar VEGFR-2 inhibition with IC50 values of 12.1, 40.3, 15.5, 13.1 and 57.4 nM, respectively, superior to that of the reference drug sorafenib (IC50 78.9 nM). Additionally, the qui-nazoline 2-carboxylate derivative bearing a fluorine substituent in middle ring (7a) showed IC50 values of 14.8 nM. Most of the new synthesized compounds are examined on NCI sixty cell lines of human cancer cells. Furthermore, molecular modeling study was administered to realize any clarification of the binding mode in the inactive VEGFR-2 conformation that demonstrates compatible binding modes similar to those of sorafenib and regorafenib. Finally, several ADME descriptors were calculated through a predictive kinetic study.
• Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking
  作者：Wagdy M. Eldehna、Mohamed Fares、Hany S. Ibrahim、Mohamed H. Aly、Suher Zada、Mamdouh M. Ali、Sahar M. Abou-Seri、Hatem A. Abdel-Aziz、Dalal A. Abou El Ella

  DOI：10.1016/j.ejmech.2015.05.040

  日期：2015.7

  In our effort to develop potent and effective agents with anti-proliferative activity towards HepG2 hepatocellular carcinoma cells with potential inhibitory activity against VEGFR-2, a novel series of 1-(4-((2oxoindolin-3-ylidene)amino)phenyl)-3-arylureas was designed and synthesized. All the newly prepared ureas 9a-x were evaluated in vitro for their anti-proliferative activity against HepG2 hepatocellular carcinoma cell line. Compounds 9a-c, 9e, 9f, 9j, 9m-o, 9t-v and 9x exhibited good activity against HepG2 cancer cells (IC50 = 1.22 +/- 0.11-8.37 +/- 0.85 mu M) comparable to that of doxorubicin and sorafinib (IC50 = 2.90 +/- 0.36 and 3.40 +/- 0.25 mu M, respectively). These thirteen compounds were further evaluated for their inhibitory activity against VEGFR-2. Compound 9x emerged as the most active counterpart against VEGFR-2 with IC50 value of 031 +/- 0.04 mu M. Furthermore, a molecular docking of the tested compounds was carried out in order to investigate their binding pattern with the prospective target, VEGFR-2 (PDB-code: 4ASD). (C) 2015 Elsevier Masson SAS. All rights reserved.